Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Actinic Keratosis
Kythera Biopharmaceuticals Completes Enrollment in Phase II Actinic Keratosis Trial
July 10th, 2007
Kythera Biopharmaceuticals, Inc. ("Kythera") announced that it has initiated and completed enrollment of its Phase II study of ATX-201 for actinic keratosis (AK). The ongoing Phase II trial is a randomized, double-blind, placebo-controlled study of 48 patients being conducted in France. Subjects with actinic keratoses on the scalp and face are undergoing at least one course of treatment with ATX-201 or placebo over a 4 to 12-week period. An assessment of efficacy, safety and tolerability will be made in multiple treatment regimens based on both primary and exploratory scales. "We hope ATX-201 will offer patients a safe and efficacious alternative to...
Source: Drug Law Weekly (2007-07-10)
|
